Podcasts about Phase

This episode is sponsored by Timeline. Support your cells and how you age with Mitopure® Gummies from Timeline. Visit https://timeline.com/FLIPPING50SHOW and save up to 39% off your Mitopure® Gummies. Other Episodes You Might Like: Previous Episode - Yoga and Bone Density: Are you just a pose away from better bones? Next Episode - What Every Woman Over 50 Needs To Know About Weight Loss and Anti Aging More Like This: Women's Health Researcher Abbie Smith-Ryan on Protein & Exercise for Longevity The Truth About Muscle and Menopause: What Every Woman Needs to Know About the Science Data Resources: Don't know where to start? Book your Discovery Call with Debra. Leave this session with insight into exactly what to do right now to make small changes, smart decisions about your exercise time and energy. Join the Flipping50 Insiders Facebook Group. Connect with other women navigating menopause fitness and get daily tips and support. Use Flipping 50 Scorecard & Guide to measure what matters with an easy at-home self-assessment test you can do in minutes. Hormonal Phase and Training Intensity has been talked about, debated, and often oversimplified—especially for women navigating midlife and menopause. Instead of opinions, myths, or influencer hot takes, this episode walks through a 2025 research that finally tested whether your cycle actually changes how hard you can train when intensity is high. If you want clarity instead of confusion about Hormonal Phase and Training Intensity, this episode is a must-listen.

Making decisions is perhaps the most important skill an entrepreneur can possess. To move from a vague idea to a structured project, Frank Kern uses a specific "Decision-Making Worksheet" to ensure every move aligns with long-term success. Phase 1: The Big Picture Before looking at the decision itself, you must ground yourself in your ultimate destination. Clarify Your 20-Year Goal: Define exactly where you want to be two decades from now. For Frank, this is building a sustainable $100M company with a minimum 35% profit margin. Define Your Purpose: Identify the "why" behind your business. Frank's purpose is to have a measurably positive impact on the global economy by changing how consumers view marketers. Identify the Decision at Hand: State clearly what you are considering. (Example: Launching a flagship program to cold media via a webinar funnel). The "Alignment" Gut Check: Ask yourself: Will this move me significantly closer to my 20-year goal? If the answer is no, stop there. Phase 2: Success Criteria & Deadlines If the decision aligns with your goals, you must define what "winning" looks like. Four Indicators of Success: List four specific results that prove the decision was right. Frank's examples include attracting qualified prospects and achieving a 3x ROI on ad spend. Set a Hard Deadline: Determine by when these success criteria must be met to turn the decision into a tracked project. Phase 3: The Benefit Analysis Analyze the impact of the decision across two different timelines: Short-Term Benefits: Immediate wins, such as gathering data, building goodwill, or turning a quick profit. Long-Term Benefits: Lasting impacts, such as business scalability, permanent list growth, and transforming the lives of clients. Phase 4: Risk Assessment (The "Reality Check") It is easy to get caught up in the "happy world" of benefits; this phase demands total honesty about potential downsides. Calculate the Cost: What is the actual financial investment required for the test? Identify What Can Go Wrong: List every fear, from suffering core business distraction to losing the entire test budget or "looking dumb." The Risk vs. Reward Comparison: Compare your "long-term benefits" against "what can go wrong." Ask: Is the potential long-term gain worth the risk of these downsides? Final Step: Immediate Action If you decide the risk is worth it, commit immediately by identifying the three next steps you can take to get the project started today.

In this episode of the Sisterhood of S.W.E.A.T., Linda is joined by Melani Sanders, creator of the viral We Do Not Care Club, People Magazine's Creator of the Year, and author of The Official We Do Not Care Club Handbook. Melani shares how midlife becomes a turning point for honesty, empowerment, and letting go of expectations that no longer serve women. Episode Highlights How the We Do Not Care Club became a viral movement for women in midlife Why midlife anger is a signal for change — not a problem to fix Letting go of societal expectations that no longer fit How perimenopause and menopause can become a reclamation of self The power of community in navigating midlife transitions   Connect with Melani Sanders Website: https://wedonotcareclub.com Instagram: https://www.instagram.com/justbeingmelani/ TikTok: https://www.tiktok.com/@justbeingmelani The Official We Do Not Care Club Handbook (Book): https://www.amazon.com/dp/1668048045 If this episode resonated, share it with a woman who needs permission to exhale, stop apologizing, and embrace this chapter fully.

This episode of The Drive Driven by Kia begins with a check-in pit stop with Europe; where, shockingly, Los Ratones won… again?! Next, Kobe, Azael, and Meteos break down everything you need to know in Patch 26.3: Mel's rework, Phase Rush buff, adjusted gold collection, and more! Meanwhile, NA pro-play has us asking quite a few questions: Is jungle out of control? Dignitas finally has a full roster, but what does that mean for their performance? And… what is Saint doing? With our final round of the Swiss Bracket and the Last Chance elimination match this weekend, we may get some answers. Oh, and have you heard of Literal “Word” Champion?LCS returns Saturday, February 7th at 1PM PT/4PM ET for TLAW vs SEN. We'll see you there!Timestamps:0:00 - Intro, Los Ratones Wins Again?!8:20 - Patch 26.3, New Changes Galore!29:18 - LYON vs C9 Recap40:57 - DIG vs SEN Recap53:21 - DSG vs FLY Recap1:04:53 - TLAW vs SR Recap1:11:53 - Looking Forward: Week 31:34:31 - Literal “Word” Champion

On this episode of "The Bruce Exclusive", Bruce reacts to the past week of Bills news and how he's approaching a whirlwind of new and sometimes competing information. Topics include Joe Brady, Brandon Beane, Terry Pegula, Josh Allen, Buffalo Bills free agents, Buffalo Bills draft picks, Buffalo Bills free agents, and more! "The Bruce Exclusive" is part of the Rumblings Cast Network! The Rumblings Cast Network family of shows includes Billieve, The Bruce Exclusive, Jamie D & Big Newt, Leading the Charge, and Unplugged. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode of The Kibbe & Friends Show brings the show back to its Phase 4 sweet spot with a full-on Dukes Review of one of the best early Georgia-era episodes of The Dukes of Hazzard: Season 1, Episode 4 — “Repo Men.” It's the perfect mix of simple Hazzard County storytelling, big laughs, and the kind of car-nerd details that only this show obsesses over — right down to the General Lee quirks, the Waylon “balladeer” narration, and why this episode still matters in Dukes lore. Rob Kibbe, Justin “Corndog” Cornette, and producer Bernie McPartland break down why “Repo Men” is a fan-favorite: Bo and Luke get pulled into a crooked car-dealer scheme involving a Rolls-Royce repo, a counterfeit ring, and some truly savage stunt payoff. Along the way, the guys spotlight what makes the Georgia episodes special — the chemistry between Bo and Luke, the early-series simplicity, and the wild practical stunts that feel like they could never happen the same way today. And of course, Corndog goes deep on General Lee specifics: the rare window-up shots, the '68 tells, and the car-history rabbit holes that turn this review into a full Dukes enthusiast session. The post K&F Show #355: Broken Arms, Bad General Lees, and Bernie on the News // Dukes VIDEO Review S1E4 “Repo Men” first appeared on The Muscle Car Place.

In this Smart Real Estate Coach master's class, I'm bringing back Brandon Cobb, founder of FBG Capital and host of Recession Resistant Real Estate Radio, to walk you through one of the most powerful and least taught niches in the business: entitling land for national homebuilders and turning dirt into 6–7 figure paydays.     Brandon shares how getting fired from his dream medical device job pushed him into entrepreneurship, why your W-2 is actually your biggest risk, and how he built a land development model where Wall Street-backed builders like Lennar, Pulte, D.R. Horton and others line up to buy his approved projects. We break down his three-phase entitlement process, why he never buys land until approvals are in place, what a typical 15-month entitlement timeline and $500K+ profit deal looks like, and who his Learn Land Development mastermind is actually for (hint: not brand-new investors or "no money down" thinkers).    If you've been looking for a way to do bigger deals without swinging hammers yourself, this episode will open your eyes to a niche that works in every real estate asset class.   Key Talking Points of the Episode   00:00 Introduction 01:31 Recession Resistant Real Estate Radio 02:24 From dream job to "accidental entrepreneur" 03:35 Lessons from losing his dream job 04:51 Fast-forward: from hustling to large land deals with national builders 06:05 Why you can't rely on a single employer anymore 07:01 The opportunity in selling land to big developers 08:25 The "fastest-growing secret" niche in real estate 11:20 Working on a minimum of 50 units per project 12:50 Phase 1: Learn what the city wants & target the right land 14:05 Phase 2: Contract & entitlements (contingent on approvals) 16:18 Phase 3: Negotiate the best possible deal with your end buyer 17:36 Concept plan: aligning the city and the builder before spending big money 18:21 Resources: Skool community + training + coaching 19:01 Training Section #1: Land Development Blueprint 19:25 Training Section #2: Capital Raising Machine 19:46 Training Section #3: Weekly group coaching calls & in-person project walks 20:25 Land entitlement: Not an entry-level, no-money-down program 22:00 3 main exit paths for entitled land 24:22 Free course: LearnLandDevelopment.com   Quotables   "Nobody was going to look out for my financial well-being but me."   "We never buy anything. That's rule number one: do not buy it until all the approvals are in place."   "This is not a no-money-down, do-your-first-real-estate deal. This is for experienced investors who are ready to do bigger deals."   Links   Land Development Accelerator https://learnlanddevelopment.com/   Recession Resistant Real Estate Radio https://open.spotify.com/show/5tuCHd862XmOCviWocPt9o   Episode 498: $20M Annual Developer Success Secrets with Brandon Cobb https://smartrealestatecoachpodcast.libsyn.com/episode-498-20m-annual-developer-success-secrets-with-brandon-cobb   QLS 4.0 - Use coupon code for 50% off https://smartrealestatecoach.com/qls Coupon code: pod   Apprentice Program https://3paydaysapprentice.com Coupon code: Podcast   Masterclass https://smartrealestatecoach.com/masterspodcast   3 Paydays Books https://3paydaysbooks.com/podcast   Strategy Session https://smartrealestatecoach.com/actionpodcast   Partners https://smartrealestatecoach.com/podcastresources

Welcome to The Times of Israel's Daily Briefing, your 20-minute audio update on what's happening in Israel, the Middle East and the Jewish world. Editor David Horovitz joins host Amanda Borschel-Dan for today's episode. An Israel Defense Forces reservist officer was seriously wounded by gunfire from Palestinian operatives in the northern Gaza Strip overnight Wednesday. The IDF responded with a series of strikes on Gaza that Palestinian media said killed at least 20 people. Horovitz weighs in on the move to Phase 2 of the Trump-brokered ceasefire -- without the demilitarization of Hamas. We also learn of the Palestinian Authority's current involvement in the Rafah Border Crossing and a kerfuffle over a logo that may indicate that ties between the PA and the council of Gazans set to rule the Strip may be tighter than anticipated. A US Navy fighter jet shot down an Iranian drone that was approaching the aircraft carrier USS Abraham Lincoln in the Arabian Sea on Tuesday, in an incident that, Horovitz suggests, shows Iran's confidence level ahead of nuclear talks set for Friday. We hear about Israel's four conditions for a "good" deal with Iran as US President Donald Trump appears to prefer dimplomacy -- for now. And finally, Israel's dairy farmers are protesting today in Jerusalem as Finance Minister Bezalel Smotrich's "reforms" seek to disband the centralized coordination mechanism that has characterized the dairy industry since the state’s founding. Hear why more dairy imports may not be the right answer. Check out The Times of Israel's ongoing liveblog for more updates. For further reading: Reservist seriously wounded in north Gaza ambush; 20 said killed as IDF strikes back 12 people let into Gaza from Egypt, of 42 who tried, on day 1 of Rafah opening – report 3 women returning to Gaza through Rafah say IDF bound, interrogated, threatened them Gaza technocratic committee replaces its logo with the PA’s; Israel fumes US downs Iranian drone flying toward aircraft carrier; PM to Witkoff: Iran can’t be trusted Shoppers face empty milk shelves as dairy farmers ramp up fight against proposed reform Subscribe to The Times of Israel Daily Briefing on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. This episode was produced by Podwaves. IMAGE: The northern Gaza Strip as seen from southern Israel, February 2, 2026. (AP Photo/Leo Correa)See omnystudio.com/listener for privacy information.

Send us a textThis week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Early, Uncut, and Ad Free for our Monthly Patrons. Subscribe today for as little as $1 a month. Thank you for supporting this independent podcast. In this episode of Mostly Superheroes, host Logan sits down with Aaron Perine — media strategist, educator, and creator behind How to Watch Free TV and Phase Hero — for a wide-ranging conversation about modern media, access, and creativity. 00:00:00 – Intro & catching up with Aaron Perine 00:02:14 – What “How to Watch Free TV” actually is 00:06:01 – Why access to media still matters 00:10:22 – Building trust with an audience 00:15:47 – From passion project to real business 00:21:36 – Launching Phase Hero 00:27:04 – Creator burnout & sustainability 00:32:18 – Local media vs algorithm culture 00:38:41 – Pop culture, tech, and curiosity 00:44:55 – What's next for Aaron 00:48:02 – Final thoughts & wrap-up Aaron shares how they built a massive audience by helping people cut the cord, why local media still matters, and what creators need to understand about sustainability, trust, and serving real communities. The conversation also dives into pop culture, technology shifts, burnout, and how curiosity can become a career. Whether you're a creator, media nerd, or just trying to make sense of the current media landscape, this episode offers real insight — no hype, no gatekeeping. Watch, listen, and subscribe at

The boys return for another week to discuss the latest in Greek football, the gift that keeps on giving.UEFA Competiton Olympiakos defeat Ajax to reach the UCL playoffsPAOK lose to Lyon under difficult circumstancesPAO draw at home to RomaSLGRAEK & Olympiakos play out a controversial draw in Agia SophiaPAOK smash PanserraikosPAO see off KifisiaThe Levadiakos train keeps on rollingOFI are in the European playoff placesAEL win three in a row & a fan is sharing out the lamb chopsGreek Cup semifinals previewPanathinaikos host PAOKOFI play LevadiakosTransfersOlympiakos makes a double signing from Rio AvePanserraikos is on a spending spreeMandas joins BournemouthPAO sign Moussa SissokoGive us a follow on:X: https://twitter.com/HellasfootyInstagram: https://www.instagram.com/hellasfooty/Facebook: https://www.facebook.com/@HellasFootyRead our blogs on: https://hellasfooty.blogspot.com/Intro music credit to George Prokopiou (Ermou Street)

SHOW SCHEDULE2-2-20261719 ROME1.Bill Roggio of the Long War Journal and Husain Haqqani discuss imminent potential US air strikes on Iran, expressing skepticism that air power alone can achieve regime change or lasting results without ground forces or sustained commitment.2.Bill Roggio and Husain Haqqani analyze Russia's offer to mediate between the US and Iran, concluding Moscow is not a credible partner and aims to distract Washington while protecting its strategic interests in Tehran.3.Alejandro Peña Esclusa reports that Cuban personnel are fleeing Venezuela as oil payments cease, signaling a crisis for Havana following Maduro's detention and the collapse of the socialist alliance that sustained both regimes.4.Alejandro Peña Esclusa explains that while Europeans criticize Maduro's capture, Venezuelans support it, hoping for the release of remaining political prisoners under a new amnesty law restoring democratic governance.5.James Holmes of the Naval War College and Gordon Chang discuss Alfred Thayer Mahan's nineteenth-century view of Hawaii as strategic opportunity, drawing parallels to modern Chinese expansionism and current interest in Greenland.6.James Holmes and Gordon Chang argue Greenland is vital for Arctic defense and mineral access, suggesting the USseeks military bases there to deny access to Russia and China in polar competition.7.Fraser Howie and Gordon Chang assert Xi Jinping's goal of making the renminbi a global reserve currency is impossible without lifting capital controls and accepting trade deficits that Beijing refuses to tolerate.8.Conrad Black criticizes the Prime Minister for labeling Canada a middle power, urging increased defense spending to secure the Northwest Passage and Arctic sovereignty against encroaching rivals.9.Edmund Fitton Brown and Bill Roggio warn that US-Iran talks ignore the mass killings of protesters, while characterizing Maliki's potential return in Iraq as a hostile act against Western interests and regional stability.10.Edmund Fitton Brown and Bill Roggio argue Saudi Arabia's refusal to allow airspace use for strikes on Iran is theatrical to avoid Iranian retaliation, noting Riyadh privately remains a dependable US partner.11.David Daoud and Bill Roggio explain Hezbollah is downplaying Gaza ties to avoid dragging Lebanon into war, prioritizing the rehabilitation of its image among the economically weary Shiite population in Lebanon.12.David Daoud and Bill Roggio note Hezbollah is refilling ranks after Israeli strikes, suggesting new leader Naim Qassem's quiet demeanor may help the group lay low and regenerate its capabilities.13.John Hardie and Bill Roggio report Russia is recruiting gamers and specialists for a new military branch, the Unmanned Systems Forces, aiming for 210,000 troops by 2030 to expand drone warfare capabilities.14.John Hardie and Bill Roggio state negotiations are deadlocked as Russia demands territory and a veto on security guarantees, while Putin ultimately seeks domination over Ukraine's geopolitical orientation and sovereignty.15.Joe Truzman and Bill Roggio describe the war as a slow boil, noting Phase 2 of the Gaza ceasefire is stalling because Hamas refuses to disarm or surrender heavy weapons to Israel.16.Ahmad Sharawi and Bill Roggio report a fragile deal where the SDF integrates into the Syrian state to avoid destruction, though tensions remain regarding Turkey and the fate of ISIS prisoners in the northeast.

Linktree: ⁠https://linktr.ee/Analytic⁠Join The Normandy For Additional Bonus Audio And Visual Content For All Things Nme+! Join Here: ⁠https://ow.ly/msoH50WCu0K⁠ In this segment of Notorious Mass Effect, Analytic Dreamz reacts to the stunning Character Trailer - "Zibai: Mortal Flesh to Kindred Earth" | Genshin Impact. HoYoverse introduces Zibai, the legendary White Horse Adeptus from Liyue—a 5-star Geo Sword DPS with amber-gold eyes, returning from lunar exile after aiding Rex Lapis in ancient wars, her form shattered like drifting dust across realms. Analytic Dreamz dissects her Lunar Phase Shift mechanics: Elemental Skill infuses Normal/Charged Attacks with unoverrideable Geo DMG, building Phase Shift Radiance for enhanced Spirit Steed's Stride—delivering dual Geo hits, one as Lunar-Crystallize DMG. DEF-scaling Burst summons Azure Canopy for massive AoE, synergizing with Hydro appliers like Columbina or Neuvillette for reaction ramps, dominating Abyss via Moonsign buffs and excess Radiance DMG spikes. Explore lore hints: "The Three Deadly Selves as specters come. In union born, in union quelled"—echoing Istaroth, celestial nails, and Natlan ties. Analytic Dreamz analyzes visuals, including the 1:38 "Horse in Motion" homage with spinning stills forming her umbrella, combat animations, voice work, and Version 6.3 Phase 2 banner (Feb 3-24, 2026) amid Lantern Rite quests. From Reddit/X hype to builds (DEF% sands, CRIT DMG goblet, Husk of Opulent Dreams), join Analytic Dreamz for frame-by-frame breakdown, power scaling, and must-pull call on this F2P Geo hypercarry reshaping Genshin Impact's meta. Support this podcast at — https://redcircle.com/analytic-dreamz-notorious-mass-effect/donationsPrivacy & Opt-Out: https://redcircle.com/privacy

Send us a textThis week on On The Pen: The Weekly Dose, we break down Pfizer's $10 billion bet on obesity medicine and whether it's shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer's once-monthly GLP-1 candidate (formerly Metsera's asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies. We also talk strategy, maintenance dosing, combination GLP-1 + amylin approaches, pricing pressures, cash-pay access, and what this all means for patients navigating a rapidly changing obesity treatment landscape. Plus, earnings week insights, where Pfizer may be headed next, and why pricing and access, not just weight-loss percentages, may end up being the real disruptors.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Joe Truzman and Bill Roggio describe the war as a slow boil, noting Phase 2 of the Gaza ceasefire is stalling because Hamas refuses to disarm or surrender heavy weapons to Israel.1898 GAZA

PREVIEW FOR LATER TODAY Guest: Joe Truzman. Truzman predicts the Gaza ceasefire's second phase will fail because Hamas refuses to disarm, creating an insurmountable obstacle despite the completion of hostage recovery.1657 PALESTINE

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review.    A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright "no" that kills a project; it's more like a "not yet." However, this Complete Response Letter raised some issues which, at first glance, don't appear to be easily fixable. Sanofi has pointed out that the issues raised in the Complete Response Letter were markedly different from the guidance they received from the FDA over the course of this approval process. Sanofi has also indicated that it would work with the FDA to find a path forward for Tolebrutinib. Dr. William Conte, an MS Specialist and a principal investigator in the Phase 3 clinical trial for Tolebrutinib, has published an article responding to the FDA's Complete Response Letter. This week, Dr. Conte joins me to discuss the FDA's action and his response to that action.  We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're at the 2026 ACTRIMS Forum  :22 Check out the official ACTRIMS Forum Insider podcast!  :42 The FDA's Complete Response Letter about Tolebrutinib  1:09 Dr. William Conte responds to the FDA's Complete Response Letter  4:09 Share this episode  38:10 Next week's episode  38:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/440 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms Find out about ABLEnow Accounts https://ablenow.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 440 Guests: Dr. William Conte Privacy Policy

In this episode we cover the lore of Darkwater, Blighted Wilds and the Maggotkin of Nurgle Battletome. Get ready for a whole lot of sickening belches,gibbering madness, and the constant draining of sinuses. And then if we have time, we'll talk all about those nurglites!   ***Thanks to GW for providing this book for us to review on the show!*** Show Notes Time Stamps What we've been up to: 3:57 The Story Phase: 18:30 Links (some links may redirect to our affiliate partners)  The Maggotkin of Nurgle Battletome can be purchased at… Hardcover at Games Workshop Contact You want to get a hold of us? Of course you do - here's how: Website: themortalrealms.com It'd really help us help you to get a review on iTunes or wherever else you listen to podcasts. Find us in your app, or head over to themortalrealms.com/review and tell us what you think. Youtube: youtube.com/themortalrealms Patreon: patreon.com/themortalrealms Twitter: @themortalrealms Davy: @Red_Zeke Paul: @pjschard Eric: @stonemonkgamer Aaron @dosaceos Josh: @jearrington  Will: @ageofSevvir Facebook: facebook.com/themortalrealms Email: mortalrealms@gmail.com Discord: themortalrealms.com/discord Shirts: https://www.themortalrealms.com/shirts Goodreads Book Club: themortalrealms.com/bookclub

Trump and Iran claim they are negotiating some kind of deal. But didn't Trump say this last June? Hear analysis from Israel, France and UK about the chances for a successful US-Iran deal. Margot in Tel Aviv joins Tony with analysis of Phase 2 of the Gaza peace deal.

Andrea Samadi revisits a conversation with neuroscientist Dr. Baland Jalal about how curiosity launched his career and how transitional sleep states fuel creativity. The episode explores sleep paralysis research and the hypnagogic window—the moments before sleep and after waking when the brain makes unexpected connections. This week, Episode 384—based on our review of Episode 224, recorded in June 2022—we'll explore: ✔ Why learning, creativity, and curiosity depend on a regulated nervous system ✔ How sleep—especially REM—creates the conditions for insight and problem-solving ✔ What happens in the brain when focus shuts down and imagination turns on ✔ Why safety, rhythm, and rest are prerequisites for learning—not rewards after it ✔ How understanding sleep changes the way we approach performance, education, and growth Listeners learn practical tips for capturing insights at the edge of sleep, setting intentions before bed, and protecting morning silence to preserve creative flashes. The episode emphasizes that learning and creativity emerge best when the nervous system feels safe and regulated. This episode launches Season 15's Phase 1 focus on regulation and safety, framing sleep, rhythm, and emotional regulation as the essential foundation for motivation, learning, and sustained performance. Welcome back to Season 15 of the Neuroscience Meets Social and Emotional Learning Podcast. I'm Andrea Samadi, and here we bridge the science behind social and emotional learning, emotional intelligence, and practical neuroscience—so you can create measurable improvements in well-being, achievement, productivity, and results. When we launched this podcast seven years ago, it was driven by a question I had never been taught to ask— not in school, not in business, and not in life: If results matter—and they matter now more than ever—how exactly are we using our brain to make these results happen? Most of us were taught what to do. Very few of us were taught how to think under pressure, how to regulate emotion, how to sustain motivation, or even how to produce consistent results without burning out. That question led me into a deep exploration of the mind–brain–results connection—and how neuroscience applies to everyday decisions, conversations, and performance. That's why this podcast exists. Each week, we bring you leading experts to break down complex science and translate it into practical strategies you can apply immediately. If you've been with us through Season 14, you may have felt something shift. That season wasn't about collecting ideas. It was about integrating these ideas into our daily life. Across conversations on neuroscience, social and emotional learning, sleep, stress, exercise, nutrition, and mindset frameworks—from voices like Bob Proctor, José Silva, Dr. Church, Dr. John Medina, and others—one thing became clear: These aren't separate tools. They're parts of one operating system. When the brain, body, and emotions are aligned, performance stops feeling forced—and starts to feel sustainable. Season 14 showed us what alignment looks like in real life. And now we move into Season 15 that is about understanding how that alignment is built—so we can build it ourselves, using predictable, science-backed principles. Because alignment doesn't happen all at once. It happens by using a sequence. By repeating this sequence over and over again, until magically (or predictably) we notice our results have changed. So this season, we're revisiting past conversations—not to repeat them—but to understand how they fit together, so we can replicate them ourselves. Because the brain doesn't develop skills in isolation. Learning doesn't happen in isolation. And neither does performance, resilience, or well-being. The brain operates as a set of interconnected systems. When one system is out of balance, everything else is affected. So Season 15 we've organized as a review roadmap, where each episode explores one foundational brain system—and each phase builds on the one before it. Season 15 Roadmap: Phase 1 — Regulation & Safety Phase 2 — Neurochemistry & Motivation Phase 3 — Movement, Learning & Cognition Phase 4 — Perception, Emotion & Social Intelligence Phase 5 — Integration, Insight & Meaning Today we begin with Phase One: Regulation and Safety. Because before learning can happen, before curiosity can emerge, before motivation or growth is possible— the brain must feel safe. That's where we are today as we embark on this journey together. I encourage us all to take notes, and apply what each phase is encouraging us to do. This is not just for you, the listener, I'm going right back myself, and revisiting each interview with a new lens. PHASE 1: REGULATION & SAFETY Staples: Sleep + Stress Regulation Core Question: Is the nervous system safe enough to learn? Anchor Episodes Episode 384 — Baland Jalal How learning begins: curiosity, sleep, imagination, creativity Bruce Perry “What happened to you?” — trauma, rhythm, relational safety Sui Wong Autonomic balance, lifestyle medicine, brain resilience Rohan Dixit HRV, real-time self-regulation, nervous system literacy EPISODE 384 — REVIEW OF EP 224 (JUNE 2022) Revisiting Our Interview with Baland Jalal Today's Episode 384 we go back to Episode 224[i], recorded in June 2022, featuring Danish neuroscientist Dr. Baland Jalal—a researcher, author, and one of the world's leading experts on sleep paralysis. Dr. Jalal is a neuroscientist affiliated with Harvard University's Department of Psychology and was previously a Visiting Researcher at Cambridge University Medical School, where he earned his PhD. His work has been featured in The New York Times, Washington Post, BBC, NBC News, The Guardian, Forbes, Reuters, PBS (NOVA), and many others. He also writes for TIME Magazine, Scientific American, Big Think, and The Boston Globe. Since our original interview, I've watched Dr. Jalal's influence expand globally. Most recently, he appeared on Jordan B. Peterson's podcast[ii], discussing Dreams, Nightmares, and Neuroscience, and on Lewis Howes' School of Greatness[iii], where he explored Dreams, Lucid Dreaming, and the Neuroscience of Consciousness—an episode that truly stretched Lewis's thinking. What stood out to me most—then and now—was Dr. Jalal's transparency about learning. At the beginning of his interview with Lewis Howes, Dr. Jalal shared how a single experience—his desire to understand his own episodes of sleep paralysis more than 20 years ago—sparked a lifelong curiosity. That curiosity led him to his local library in Copenhagen and ultimately transformed his entire career path in ways he could never have imagined as a young man spending time on the streets. That honesty resonated deeply with me. Before Google, I remember sitting in a local library in Arizona around that same time, trying to understand the mysteries of the world—from the Great Pyramid of Giza to Stonehenge—reading everything I could get my hands on. Like Dr. Jalal, I was curious about many things I didn't understand, but my path didn't start with neuroscience or learning science, which came later for me. We all begin somewhere. Let's go to our first clip from Dr. Baland Jalal, where he shares how his love of learning truly began.

I know 2026 feels like it ihas been here for months, but only a few weeks ago we were celebrating the nephrology accomplishments of 2025. The New Filtrate came together to review the year.The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn Editor in Chief of Kidney International Case ReportsAnna Gaddy (@AnnaGaddy) Winner of NephJC Rookie of the Year 2020Nayan Arora (@CaptainChloride.bsky.social)AC (@medpeedskidneys.bsky.social)Vipin Verghese (@vipvargh.bsky.social) co-winner of NephJC Engaged Scientist of the Year in 2021Brian Rifkin (@brianrifkin.bsky.social) Co-Editor in Chief NephJC. Winner of NephJC Rookie of the Year 2021Cristina Popa (@NephroSeeker) Co-Editor in Chief NephJC. Wwinner of NephJC Rookie of the Year 2022 and MVP 2023Editing and Show Notes byAnna Gaddy and Joel TopfThe Kidney Connection written and performed by Tim YauShow NotesTop Stories in Nephrology 2025 (NephJC)First Top sories in Nephrology 2010! (Renal Fellow Network)Links to all of the Top Stories in Nephrology, hosted on NephJC since 2017 (NephJC)1. IgA NephropathyVISIONARY: Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial (NEJM)ORIGIN 3: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (NEJM)APPLAUSE-IgA Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (NEJM)Aliza M. Thompson, MD, MS (ASN) 2. Lupus NephritisREGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis (NEJM)3. Nobel prize winner and peripheral immune tolerance4. Xenotransplantation5. GLP1ra RevolutionRemodel REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide (Kidney International)SURPASS-CVOT Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases (Kidney Week abstract in JASN)Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (KFF survey)6. GDMT implementation in CKD: lessons learnt from CONFIDENCE and MIRO-CKDConfidence Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (NEJM)MIRO-CKD Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial (The Lancet)7. Flozin Meta analysisSMART-C. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria. A Meta-Analysis (JAMA)SMART-C. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria. A Meta-Analysis (JAMA)8. Paradigm Shift: Aiming for CKD Remission9. Fish Oil and DialysisPISCES Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM)10. Decline in Dialysis Patients in the United StatesUSRD 2025 Annual Data Report (USRDS)Tubular SecretionSwapnil Hiremath Alien Earth on FX Hulu (Wikipedia)AC A Christmas Carol by Charles Dickens (Wikipedia) and The Muppet Christmas Carol (Wikipedia)Anna Monty Don (Wikipedia)Nayan Back Street Boys at The Sphere (Wikipedia)Brian Marty Supreme (Wikipedia)Cristina The Yellow Tie (Wikipedia)Vipin Stranger Things, good for a four year old? (Wikipedia)Joel Crash Course: The Universe with Katie Mack and John Green (Apple PodCasts)

On today's HighWire, Former CDC Director Robert Redfield is now saying the quiet part out loud, admitting we were right about mRNA and spike protein. Also, Del Celebrates RFK Jr.'s Announcement of 21 new members of the Interagency Autism Coordinating Committee (IACC), the committee responsible for coordinating the government's autism research and response. This is huge, and Del has the details.Then, we examine Moderna's announcement that it is halting new Phase 3 vaccine trials, citing reduced market incentives under increased federal oversight. What does this decision reveal about safety testing, accountability, and public health priorities?Also, a deep dive into the UK's newly announced AI surveillance system — described by officials as a “panopticon.” We unpack the origins of the term and what it signals about the future of mass surveillance.Plus, as fraud investigations rock Minnesota, autism education providers are facing devastating funding cuts. Jennifer Larson of Holland Center joins Del to explain how legitimate, long-standing programs are now at risk — and how families are paying the price.Guest: Jennifer LarsonBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Most detox advice online is wrong — and can actually make you feel worse. In this episode, we break down how true liver detoxification really works through Phase 1 activation, Phase 2 processing, and Phase 3 elimination. You'll learn why detox symptoms happen, why constipation blocks detox pathways, and how issues like histamine intolerance, estrogen dominance, migraines, and chemical sensitivity connect to specific detox routes like methylation, sulfation, and glucuronidation. We also explain why throwing NAC, B vitamins, and “detox supplements” at your body without proper elimination support can backfire — and what to support first instead. *** CONNECT:

Broadcast from KSQD, Santa Cruz on 1-29-2026: An emailer asks about hemorrhoids affecting 2 relatives,a 60-year-old man and his 20-year-old daughter, with the daughter also experiencing constipation worsened by fiber supplements. Dr. Dawn explains hemorrhoids are essentially varicose veins of the anus, with 102 genetic regions identified affecting blood vessel and smooth muscle strength. She emphasizes that fiber supplements without adequate water create "cement in the pipe"—recommending 16-24 ounces of water with supplements and 2 liters of clear water daily. Miralax also requires sufficient hydration to work. Key strategies include exercise to stimulate gut motility, staying off the toilet if unable to produce results, using a standing desk to reduce prolonged sitting pressure, and triggering the gastrocolic reflex by eating. Dr. Dawn discusses research on the "volatilome"—volatile organic compounds in breath that reflect gut microbiome composition. Researchers using sterile mice colonized with specific bacteria could identify bacterial fingerprints through breath analysis. The technique identified disease-associated compounds for tuberculosis and malaria, and correlated specific gut bacteria with asthma severity in children. The research suggests breath testing could eventually replace stool samples for microbiome assessment and disease screening. She explains detoxification biochemistry, distinguishing between water-soluble toxins easily filtered by kidneys and fat-soluble toxins requiring liver transformation. Phase one converts fat-soluble molecules into reactive intermediates—dangerous if they linger—while phase two attaches water-soluble molecules like glutathione to neutralize them for excretion. Supporting phase two requires green tea, cruciferous vegetables, garlic, and curcumin. She cautions against extended fasting for detox, especially over age 50, as it depletes the body's detoxification resources and muscle mass. A caller asks about alkaline versus acidic water. Dr. Dawn explains you cannot alkalinize blood since kidneys maintain pH, but alkaline urine is beneficial. Rather than expensive alkaline waters, adding a pinch of baking soda achieves the same effect. Eating a 3:1 ratio of fruits, vegetables, and grains to animal products naturally alkalinizes urine. She notes lemons paradoxically alkalinize because kidneys overcompensate for the acid load. A caller asks about managing heart disease after receiving a third stent. Dr. Dawn recommends the Mediterranean diet over DASH for cardiac patients, as Mediterranean emphasizes fish, whole grains, and fiber that binds cholesterol for excretion, while DASH focuses on calcium for hypertension. She encourages exploring exercise options through meetup.com groups and the hospital's lifestyle center, emphasizing that consistent effort can reduce biological age by 3-5 years regardless of chronological age.

Royalmount is not just "doing fine" it is accelerating. In this episode Axel Monsaingeon sits down with Michael Stroll, Partner at Carbonleo and SVP Leasing, to break down what actually drives a successful mixed use destination in Montreal. They explore how consumer habits are changed, why occupancy momentum matters more than first month headlines, and how the right tenant mix, events, and access strategy can reposition an asset quickly. You will hear the measurable results behind the Royalmount lease up, the expansion logic for phase two retail, why a hotel on site makes sense, and how Class A office demand is being reshaped by commute patterns and lifestyle convenience. If you work in development, leasing, investment, or brokerage, this conversation is a masterclass in building durable demand through placemaking and long term vision. Topics & Timestamps

The Champions League league phase closed out in full Matchday Mayhem, and the boys are here to break it all down. Jimmy Conrad, Charlie Davies, and Tony Meola unpack an unhinged UCL matchday 8 that concluded with a dramatic goalkeeping goal for Benfica - and of course Tony has strong opinions about it (05:54)! Marvin Dills became the latest American to make his bow in the competition (10:55). Malik Tillman stole the show with his second brace of the competition (11:54), while Folarin Balogun and Weston McKennie went head-to-head in a tense scoreless draw as Monaco and Juventus moved on (18:10). Club Brugge added insult to injury for Tim Weah and Marseille (27:21), and it was heartbreak for Sergiño Dest and Ricardo Pepi as PSV crashed out (35:15). The crew then looks ahead to the Champions League Knockout Playoffs, breaking down potential matchups for the Americans still standing (34:37), before shifting their focus to today's Europa League action (40:30). And finally, it's time for a USMNT attacking midfield check-in (47:17). With Mauricio Pochettino's depth chart taking shape, the guys dig into the club form of Gio Reyna and Brenden Aaronson, debating where each stands heading into the next international window (59:10). Call It What You Want is available for free on the Audacy app as well as Apple Podcasts, Spotify and wherever else you listen to podcasts.  Follow the Call It What You Want team on X:⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@JimmyConrad⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠ @CharlieDavies9⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠@TMeola1⁠⁠⁠⁠⁠⁠⁠ Visit the ⁠betting arena on CBSSports.com⁠ for all the latest in ⁠sportsbook reviews⁠ and ⁠sportsbook promos⁠ for ⁠betting on soccer⁠ For more soccer coverage from CBS Sports, visit ⁠https://www.cbssports.com/soccer/⁠ To hear more from the CBS Sports Podcast Network, visit ⁠https://www.cbssports.com/podcasts/⁠ Watch UEFA Champions League, UEFA Europa League, UEFA Europa Conference League, UEFA Women's Champions League, EFL Championship, EFL League Cup, Carabao Cup, Serie A, Coppa Italia, CONCACAF Nations League, CONCACAF World Cup Qualifiers, Lamar Hunt U.S. Open Cup, NWSL, Scottish Premiership, AFC Champion League by subscribing to ⁠⁠⁠⁠⁠⁠⁠⁠Paramount+⁠⁠⁠⁠⁠⁠⁠⁠ Visit the betting arena on CBS Sports.com: ⁠https://www.cbssports.com/betting/⁠ For all the latest in sportsbook reviews: ⁠https://www.cbssports.com/betting/news/sportsbook-promos/⁠ And sportsbook promos: ⁠https://www.cbssports.com/betting/news/sportsbook-promos/ To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Senate does not advance a package of six FY2026 spending bills ahead of Friday's deadline to avoid a partial government shutdown, but Senators and the White House are reportedly working on a deal to pass five bills as a group and separate out Homeland Security funding and extend it for a short period to allow for more talks on how to reform ICE; President Donald Trump holds a Cabinet meeting, but does not call on Homeland Security Secretary Kristi Noem or Attorney General Pam Bondi to speak and does not take any reporters' questions; White House Border Czar Tom Homan says he has ordered federal immigration authorities to work on an eventual drawdown plan for federal law enforcement in Minnesota, operations until then will be targeted and he is “staying ‘til the problem's gone”; Suspect in the attack on Rep. Ilhan Omar (D-MN) at a town hall this week faces federal charges, as she blames President Trump's rhetoric for threats to her safety; updates from the White House Cabinet meeting on the war in Ukraine, U.S. military build up near Iran, and the Israel-Hamas ceasefire, Phase 2; President's National Security Agency Director nominee testifies before the Senate Intelligence Committee; Senate Agriculture Committee passes a bill to regulate the digital assets market; some in Europe are talking about boycotting the World Cup matches in the U.S. Learn more about your ad choices. Visit megaphone.fm/adchoices

B shares her take on dating during the "in-between phase." That space between raising teenagers and the empty nest of kids at college. PLUS: Thinking about what YOU bring to the table and how men can be even more emotional than women. See omnystudio.com/listener for privacy information.

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comFind out how the future of AI could impact your retirement during Zach Abraham's free “New Year Reset” live webinar This Thursday January 29th 3:30pm Pacific. Register at KnowYourRiskPodcast.com.Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThere's a lot more that needs to be done. Thank God we left the WHO, but they haven't left us, I'll explain...Episode links:I FULLY support the Trump Admin pulling out of the World Health Organization and was proud to see legislation I introduced five years ago during COVID come to fruition. The WHO covered up on behalf of the ChiComms and pushes a leftist globalist agenda. Defund Tyranny.WHO SAYS: “We never imposed lockdowns or vaccine passports.” ALSO WHO: “You must follow lockdowns and use vaccine passports.” The WHO pushed policies that controlled movement and daily life, then denied it. People are NOT buying it.Bruce Alyward, senior advisor to the Director General of the World Health Organisation, pretends to not hear the question when asked if WHO would reconsider Taiwan's membership. Interviewer asks again and he shuts down meeting."We cannot afford to trust the WHO anymore." - Dr. Wahome Ngare from Kenya exposes a World Health Organization sterilization effort disguised as a vaccination campaign.BREAKING: New Study Reveals WHY Regulators Missed the DNA Contamination in mRNA Vaccinesl The answer was hiding in plain sight—and it explains everything.The CEO of Moderna says he is deeply disappointed that the company's vaccines for children are no longer being recommended. He openly confesses that the decline in demand has hurt the vaccine business. He says Moderna no longer expects to invest in new Phase 3 vaccine studies anytime soon because it no longer has access to the U.S. market.

B shares her take on dating during the "in-between phase." That space between raising teenagers and the empty nest of kids at college. PLUS: Thinking about what YOU bring to the table and how men can be even more emotional than women. See omnystudio.com/listener for privacy information.

Are you wondering whether Wonder Man is worth your time? In this episode, we break down Marvel's latest Disney+ series, give you the essential background on the character, and explain what you actually need to know before diving in. From Simon Williams' comic book origins to his surprising connections with Vision, Scarlet Witch, and the Avengers, we cover the fun facts, controversies, and powers that shaped Wonder Man long before his MCU debut. We also dig into how Wonder Man fits into the MCU under the Marvel Spotlight banner—designed to be more grounded, character-driven, and accessible without deep MCU homework. Starring Yahya Abdul-Mateen II as a struggling actor hiding dangerous superpowers, and Ben Kingsley returning as Trevor Slattery, the series leans hard into Hollywood satire, mentorship, and the bizarre "Doorman Clause" that bans super-powered people from acting. Our reactions are… mixed. While the show shines as a personal story about ambition, insecurity, and creative survival—anchored by a standout performance from Ben Kingsley—it struggles with tone, realism, and the weight of its MCU identity. We talk about what works, what doesn't, and whether Wonder Man feels like a forgotten experiment or a meaningful setup for something bigger down the road. Watch the YouTube version here for the best experience. Listen to the podcast episode here: Written WONDER MAN Review Wonder Man is the 19th television series in the Marvel Cinematic Universe (including both live-action and animated projects) and arrives as part of Phase 6. The series was created by Destin Daniel Cretton (Shang-Chi and the Legend of the Ten Rings) and Andrew Guest (Hawkeye, Community, Brooklyn Nine-Nine). Yahya Abdul-Mateen II, crossing superhero franchises after playing Black Manta in DC's Aquaman films, stars as Simon Williams, a struggling actor auditioning for the lead in a remake of Wonder Man, a low-budget 1980s action film that Simon once bonded over with his father. Simon carries a dangerous secret: he has explosive superpowers that he can't fully control. Worse, he must keep those powers hidden if he wants any chance at an acting career thanks to the Doorman Clause, a rule that bars super-powered individuals from working as actors. One episode dives into the origins of this clause, and it's easily among the series' most entertaining and imaginative chapters. Ben Kingsley returns as Trevor Slattery, the infamous actor hired to portray the Mandarin in Iron Man 3. Since then, the character has appeared in the Marvel short All Hail the King and film Shang-Chi and the Legend of the Ten Rings. Here, Trevor is once again chasing relevance—and is also auditioning for a role in the Wonder Man remake. Interestingly, the series never clearly states where it fits into the MCU timeline. There are only light references—photos on walls, casual mentions of "shield throwing." Frankly, that restraint is welcome. It's firmly set in the present day on the main MCU Earth, and that's more than enough. Had this been set on another timeline or Earth, this review probably wouldn't exist. Character Over Capes At its core, this is a strong, personal story about two people supporting each other in a brutal industry. Simon approaches acting with intense seriousness—reminiscent of Dustin Hoffman's character in Tootsie—while Trevor, as a mentor figure, pushes him to loosen up and trust the words on the page. Wonder Man is far more interested in the relationship between Simon Williams and Trevor Slattery than in building a new costumed icon. Through their conversations, the series thoughtfully explores what it actually means to be an actor. Abdul-Mateen II and Kingsley make for an engaging, surprisingly balanced duo. The show wisely avoids leaning into easy odd-couple clichés, which elevates their dynamic. If you enjoyed the behind-the-scenes look at show business in The Studio or Hacks, there's a lot here to like. Wonder Man ups the stakes by adding uncontrollable superpowers into an already stressful industry where almost nothing goes your way. Tone & Reality Gaps Tonally, Wonder Man struggles. It can't always decide whether it wants to be serious and emotional or silly and farcical. It oscillates between the two. The dialogue is often grounded and well-written, but the situations frequently feel forced—bent to serve the script rather than emerging naturally from reality. Living in Los Angeles, where the series is set, makes some of these moments especially hard to ignore. Being under a tight deadline to submit an audition tape and deciding to drive from Hollywood to Malibu and back—congratulations, you've just wasted three hours. These issues extend to the on-set scenes. Having worked in the film industry, many of these moments rang false. A day player wouldn't halt production because they have extensive notes. There are numerous story hiccups where disbelief must be suspended simply to keep the plot moving. A test audience likely would have flagged many of these. Performances & Standout Moments Any time Ben Kingsley is on screen, he's impossible not to root for. Simon, by contrast, is difficult to like until the final two episodes. That's clearly intentional—he's closed off and emotionally blocked—but watching someone repeatedly sabotage themselves is frustrating, even if it's thematically justified. One unquestionable highlight is the episode centered on the Doorman Clause, "Doorman". Josh Gad's appearance, along with his reworked version of "In Summer," is delightful and injects much-needed energy and creativity into the series. Release Strategy & Final Verdict Marvel continues to undermine its TV output with its release strategy. Ironheart dropped its six episodes across two days. Echo released all five at once. Wonder Man follows suit with all eight episodes dropping in a single day. The result? These shows are consumed quickly and forgotten just as fast. By the time Daredevil Season 2 arrives in March, this will likely be one of those "Oh yeah… what happened on Wonder Man again?" series.I went in with an open mind and high expectations—this is Marvel, after all. In the end, I liked Wonder Man, but too much got in the way of loving it. SPONSORS Small World Vacations is an official sponsor of Skywalking Through Neverland. Contact them for a no obligation price quote at www.smallworldvacations.com. Tell them Skywalking Through Neverland sent you.

In this episode El Bandido continues our Deer Foundation series, part of our Whitetail Strategies series, by reviewing a new book, The Total Deer Hunter Manual by Field & Stream. This has been fun to go through as it contains 301 essential skill for any deer hunter. We'll review the skills together and see what we can learn, where we have common ground and where perhaps we may have a different… Source

Most B2B podcasts fail because they skip strategy and jump straight to recording. In this solo episode of Pipe Dream, host Jason Bradwell breaks down B2B Better's Podcast to Pipeline Framework, a six-step system designed to turn a podcast from a “nice content idea” into a revenue-generating GTM asset. Jason's core point is that marketing strategy matters more than microphones. The goal isn't to ship episodes, it's to create commercial momentum. That's why B2B Better positions itself as a podcast marketing agency, not just a production company: a podcast should drive pipeline, create revenue, and ultimately turn a profit. Anything else becomes a vanity project that dies after a handful of episodes. From there, he walks through the six phases: 1) Strategy development (the most skipped step). Instead of asking what gear to buy, brands should define what success looks like, who the audience is, and what messages matter. Jason runs strategy workshops with stakeholders across marketing, sales, product, and leadership to build a “show blueprint” that clarifies the what/why/who/how and prevents random feedback from derailing things later. 2) Funnel mapping. Most companies treat podcasts as top-of-funnel awareness only, but Jason argues podcasts can move buyers through awareness, consideration, evaluation, and conversion when you map content intentionally. He introduces B2B Better's distribution grid to align segments and content to different buyer awareness stages and distribution paths. 3) Pre-production. This is the setup work that makes recording smooth: scripting, guest booking and research, and establishing visual/audio treatments so the show feels consistent and intentional. 4) Creative treatment. Here Jason draws a key distinction: production is editing raw footage into a finished episode, while producing is editorial oversight and strategic control to ensure the episode hits the right messages. Many brands only buy production, but what they really need is a producer who can guide the conversation and keep the content aligned to the goal. 5) Integrated campaigns. Distribution and promotion shouldn't be “repurpose one episode into 100 assets.” Jason pushes back on that trend because it often creates redundant content that doesn't move the needle. Distribution has to match the objective: brand awareness might mean short clips plus paid spend; ABM might mean sales enablement and targeted account plays. 6) Reporting and optimisation. A show isn't static. Someone needs to review performance at the episode, channel, and show level with what's working, what isn't, and what market feedback is signaling and then feed that back into strategy (stay the course, pivot, or double down). If you're launching a B2B podcast or already have one that feels like it's going nowhere, Jason's framework is a practical way to treat podcasting like the GTM asset it should be, align every phase to commercial outcomes, and avoid the “six episodes then abandon it” trap. 00:00 - Introduction: From concept to commercial results 01:30 - Why B2B Better is a podcast marketing agency 03:00 - Phase 1: Strategy development and the show blueprint 06:00 - Phase 2: Funnel mapping and the distribution grid 09:00 - Phase 3: Pre-production essentials 11:00 - Phase 4: Creative treatment - producing vs production 14:00 - Phase 5: Integrated campaigns and smart distribution 17:00 - Phase 6: Reporting and optimisation 20:00 - How to get started with B2B Better Connect with Jason Bradwell on LinkedIn Check out Jason's several tools in building guest lists: HubSpot CRM Clay Apollo Explore B2B Better website and the Pipe Dream podcast 

George Mekhail, Managing Director of Bitcoin for Corporations at BTC Inc, explains why Bitcoin is no longer being ignored by institutions — it's being actively challenged.In this interview from the Bitcoin MENA Conference, George breaks down why corporate Bitcoin treasury companies are being targeted, how global corporate adoption is accelerating, the role of advocacy in protecting Bitcoin companies, and whether the traditional four-year Bitcoin cycle still applies.Topics covered include: • Why institutions are pushing back against Bitcoin • Corporate Bitcoin adoption around the world • Regulatory friction in Europe vs the United States • The MSCI proposal targeting Bitcoin-heavy balance sheets • Whether Bitcoin's four-year cycle is changing

Retatrutide is being called the next big leap in medical weight loss...but does the hype actually match the human data? In this episode, we break down what retatrutide is, how it works as a triple-agonist drug, and what current human trials really show in terms of fat loss, metabolic health, and side effects. We also dive into potential benefits beyond the scale, realistic expectations compared to GLP-1 drugs, and the uncomfortable but necessary question: is retatrutide headed toward widespread misuse and abuse? This is an evidence-based, no-nonsense conversation separating clinical promise from influencer exaggeration. *** Phase 3 trials are underway but not completed, Coach Vinny misspoke in the background and said passed phase 3 instead of phase 2*** Coach VinnyEmail: vinny@balancedbodies.ioInstagram: vinnyrusso_balancedbodiesFacebook: Vinny Russo Dr. ErynEmail: dr.eryn@balancedbodies.ioInstagram: dr.eryn_balancedbodiesFacebook: Eryn Stansfield LEGION 20% OFF CODEGo to https://legionathletics.com/ and use the code RUSSO for 20% off your order!

Are you wondering whether Wonder Man is worth your time? In this episode, we break down Marvel's latest Disney+ series, give you the essential background on the character, and explain what you actually need to know before diving in. From Simon Williams' comic book origins to his surprising connections with Vision, Scarlet Witch, and the Avengers, we cover the fun facts, controversies, and powers that shaped Wonder Man long before his MCU debut. We also dig into how Wonder Man fits into the MCU under the Marvel Spotlight banner—designed to be more grounded, character-driven, and accessible without deep MCU homework. Starring Yahya Abdul-Mateen II as a struggling actor hiding dangerous superpowers, and Ben Kingsley returning as Trevor Slattery, the series leans hard into Hollywood satire, mentorship, and the bizarre "Doorman Clause" that bans super-powered people from acting. Our reactions are… mixed. While the show shines as a personal story about ambition, insecurity, and creative survival—anchored by a standout performance from Ben Kingsley—it struggles with tone, realism, and the weight of its MCU identity. We talk about what works, what doesn't, and whether Wonder Man feels like a forgotten experiment or a meaningful setup for something bigger down the road. Watch the YouTube version here for the best experience. Listen to the podcast episode here: Written WONDER MAN Review Wonder Man is the 19th television series in the Marvel Cinematic Universe (including both live-action and animated projects) and arrives as part of Phase 6. The series was created by Destin Daniel Cretton (Shang-Chi and the Legend of the Ten Rings) and Andrew Guest (Hawkeye, Community, Brooklyn Nine-Nine). Yahya Abdul-Mateen II, crossing superhero franchises after playing Black Manta in DC's Aquaman films, stars as Simon Williams, a struggling actor auditioning for the lead in a remake of Wonder Man, a low-budget 1980s action film that Simon once bonded over with his father. Simon carries a dangerous secret: he has explosive superpowers that he can't fully control. Worse, he must keep those powers hidden if he wants any chance at an acting career thanks to the Doorman Clause, a rule that bars super-powered individuals from working as actors. One episode dives into the origins of this clause, and it's easily among the series' most entertaining and imaginative chapters. Ben Kingsley returns as Trevor Slattery, the infamous actor hired to portray the Mandarin in Iron Man 3. Since then, the character has appeared in the Marvel short All Hail the King and film Shang-Chi and the Legend of the Ten Rings. Here, Trevor is once again chasing relevance—and is also auditioning for a role in the Wonder Man remake. Interestingly, the series never clearly states where it fits into the MCU timeline. There are only light references—photos on walls, casual mentions of "shield throwing." Frankly, that restraint is welcome. It's firmly set in the present day on the main MCU Earth, and that's more than enough. Had this been set on another timeline or Earth, this review probably wouldn't exist. Character Over Capes At its core, this is a strong, personal story about two people supporting each other in a brutal industry. Simon approaches acting with intense seriousness—reminiscent of Dustin Hoffman's character in Tootsie—while Trevor, as a mentor figure, pushes him to loosen up and trust the words on the page. Wonder Man is far more interested in the relationship between Simon Williams and Trevor Slattery than in building a new costumed icon. Through their conversations, the series thoughtfully explores what it actually means to be an actor. Abdul-Mateen II and Kingsley make for an engaging, surprisingly balanced duo. The show wisely avoids leaning into easy odd-couple clichés, which elevates their dynamic. If you enjoyed the behind-the-scenes look at show business in The Studio or Hacks, there's a lot here to like. Wonder Man ups the stakes by adding uncontrollable superpowers into an already stressful industry where almost nothing goes your way. Tone & Reality Gaps Tonally, Wonder Man struggles. It can't always decide whether it wants to be serious and emotional or silly and farcical. It oscillates between the two. The dialogue is often grounded and well-written, but the situations frequently feel forced—bent to serve the script rather than emerging naturally from reality. Living in Los Angeles, where the series is set, makes some of these moments especially hard to ignore. Being under a tight deadline to submit an audition tape and deciding to drive from Hollywood to Malibu and back—congratulations, you've just wasted three hours. These issues extend to the on-set scenes. Having worked in the film industry, many of these moments rang false. A day player wouldn't halt production because they have extensive notes. There are numerous story hiccups where disbelief must be suspended simply to keep the plot moving. A test audience likely would have flagged many of these. Performances & Standout Moments Any time Ben Kingsley is on screen, he's impossible not to root for. Simon, by contrast, is difficult to like until the final two episodes. That's clearly intentional—he's closed off and emotionally blocked—but watching someone repeatedly sabotage themselves is frustrating, even if it's thematically justified. One unquestionable highlight is the episode centered on the Doorman Clause, "Doorman". Josh Gad's appearance, along with his reworked version of "In Summer," is delightful and injects much-needed energy and creativity into the series. Release Strategy & Final Verdict Marvel continues to undermine its TV output with its release strategy. Ironheart dropped its six episodes across two days. Echo released all five at once. Wonder Man follows suit with all eight episodes dropping in a single day. The result? These shows are consumed quickly and forgotten just as fast. By the time Daredevil Season 2 arrives in March, this will likely be one of those "Oh yeah… what happened on Wonder Man again?" series.I went in with an open mind and high expectations—this is Marvel, after all. In the end, I liked Wonder Man, but too much got in the way of loving it. SPONSORS Small World Vacations is an official sponsor of Skywalking Through Neverland. Contact them for a no obligation price quote at www.smallworldvacations.com. Tell them Skywalking Through Neverland sent you.

From completing Phase 1 drilling at the Gowganda West Project, which builds on the company's early drill discovery, to advancing plans for a diverse and balanced commodities portfolio, iMetal Resources (TSXV: IMR | OTCQB: IMRFF | FRA: A7VA) stands out as a dynamic micro-cap with strong long-term potential.Learn more as President & CEO Saf Dhillon shares key exploration updates, explains what they mean for iMetal Resources' growing momentum, and outlines the company's strategy for future growth.Discover: https://imetalresources.ca/Watch the full YouTube interview here: https://youtu.be/qWHzboRo6JIAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Questcorp Mining (CSE: QQQ | OTCQB: QQCMF | FSE: D910) is signaling strong potential for long-term growth, having recently released highlights from its Phase 1 Drill and Exploration Program at the La Union Project in Sonora, Mexico. Founding Director, President, and CEO Saf Dhillon shares why this milestone sets the company apart, what the team discovered in terms of gold, silver, zinc, and lead mineralization, and why the company is optimistic about future discoveries across targets.Explore:  https://questcorpmining.ca/Watch the full YouTube interview here: https://youtu.be/mdbWjhZNINAAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

On this week’s episode, we’re continuing our Guidelines Series exploring the 2022 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. If you missed our first episode in the series, give it a listen to hear about the most recent recommendations regarding Pulmonary Hypertension definitions, screening, and diagnostics. Today, we’re talking about the next steps after diagnosis. Specifically, we’ll be discussing risk stratification, establishing treatment goals, and metrics for re-evaluation. We’ll additionally introduce the mainstays of pharmacologic therapy for Pulmonary Hypertension. Meet Our Co-Hosts Rupali Sood  grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a pulmonary and critical care medicine fellow. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs, and bedside medical education. Tom Di Vitantonio  is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered. Key Learning Points 1) Episode Roadmap How to set treatment goals, assess symptom burden, and risk-stratify patients with suspected/confirmed pulmonary arterial hypertension (PAH). What tools to use to re-evaluate patients on treatment Intro to major PAH medication classes and how they map to pathways. 2) Case-based diagnostic reasoning Patient: 37-year-old woman with exertional dyspnea, mild edema, abnormal echo, telangiectasias + epistaxis → raises suspicion for HHT (hereditary hemorrhagic telangiectasia) and/or early connective tissue disease. Key reasoning move: start broad (Groups 2–5) and narrow using history/exam/testing. In a young patient without obvious left heart or lung disease, think more about Group 1 PAH (idiopathic/heritable/associated). HHT teaching point: HHT can cause PH in more than one way: More common: high-output PH from AVMs (often hepatic/pulmonary) Rare (1–2% mentioned): true PAH phenotype (vascular remodeling; associated with ALK1 in some patients), behaving like Group 1 PAH. 3) Functional class assessment WHO Functional Class: Class I: no symptoms with ordinary activity, only with exertion Class II: symptoms with ordinary activity Class III: symptoms with less-than-ordinary activity (can't do usual chores/shopping without dyspnea) Class IV: symptoms at rest Practical bedside tip they give: Ask if the patient can walk at their own pace or keep up with a similar-age peer/partner. If not, think Class II (or worse). 4) Risk stratification at diagnosis: why, how, and which tools Big principle: treatment choices are driven by risk, and the goal is to move patients to low-risk quickly. ESC/ERS approach at diagnosis (as described): Use a 3-strata model predicting 1-year mortality: Low: 20% ESC/ERS risk assessment variables (10 domains discussed): Clinical progression, signs of right heart failure, syncope WHO FC Biomarkers (NT-proBNP) Exercise capacity (6MWD) Hemodynamics Imaging (echo; sometimes cardiac MRI) CPET (peak VO₂; VE/VCO₂ slope) They note: even if you don't have everything, the calculator can still be useful with ≥3 variables. REVEAL 2.0: Builds on similar core variables but adds further patient context (demographics, renal function, BP, DLCO, etc.) Case result: both tools put her in intermediate risk (ESC/ERS ~1.6; REVEAL 2.0 score 8), underscoring that mild symptoms can still equal meaningful mortality risk. 5) Treatment goals and follow-up philosophy What they explicitly prioritize: Help patients feel better, live longer, and stay out of the hospital Use risk tools to communicate prognosis and to track improvement Reassess frequently (they mention ~every 3 months early on) until low risk is achieved “Time-to-low-risk” is an important treatment goal Also emphasized: The diagnosis is psychologically heavy; patients need clear counseling, reassurance about the plan, and connection to support groups. 6) Medication classes for the treatment of PAH Nitric oxide–cGMP pathway PDE5 inhibitors: sildenafil, tadalafil Soluble guanylate cyclase stimulator: riociguat Important safety point: don't combine PDE5 inhibitors with riociguat (risk of significant hypotension/hemodynamic effects) Endothelin receptor antagonists (ERAs) “-sentan” drugs: bosentan (less used due to side effects/interactions), ambrisentan, macitentan Teratogenicity emphasized Hepatotoxicity that requires LFT monitoring Can cause fluid retention and peripheral edema Prostacyclin pathway Prostacyclin analogs/agonists: Epoprostenol (potent; short half-life; IV administration) Treprostinil (IV/SubQ/oral/inhaled options) Selexipag (oral prostacyclin receptor agonist) 7) Sotatercept (post-guidelines) They note sotatercept wasn't in 2022 ESC/ERS but is now “a game changer” in practice: Mechanism: ligand trap affecting TGF-β signaling / remodeling biology Positioned as potentially more disease-modifying than pure vasodilators Still evolving: where to place it earlier vs later in regimens is an active question in the field 8) How risk category maps to initial treatment intensity General approach they outline: High risk at diagnosis: parenteral prostacyclin (IV/SubQ) strongly favored, often aggressive early Intermediate risk: at least dual oral therapy (typically PDE5i + ERA); escalate if not achieving low risk Low risk: at least one oral agent; many still use dual oral depending on etiology/trajectory For the case: intermediate-risk → start dual oral therapy (they mention tadalafil + ambrisentan as a typical choice), reassess in ~3 months; add a third agent (e.g., selexipag/prostacyclin pathway) if not low risk.  References and Further Reading Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672; PMCID: PMC6584967. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892. doi: 10.1001/jama.2022.13696. PMID: 35412560.

This Biotech CEO Is Creating Advanced & Personalized Therapies To Fight Cancer.Full Name: Thomas JensenTitle: Chief Executive Officer, Allarity Therapeutics Ticker: $ALLRWebsite: https://www.allarity.com/Bio:Thomas Jensen is the Chief Executive Officer of Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage biopharmaceutical company advancing personalized cancer therapies. He was appointed CEO in December 2023 after nearly a decade as Chief Technology Officer, during which he helped pioneer the company's proprietary Drug Response Predictor (DRP®) platform.With over 20 years in the biotech and precision medicine space, Thomas has led Allarity through a focused strategic transformation centered on stenoparib—a first-in-class dual PARP/tankyrase inhibitor currently in Phase 2 trials for advanced ovarian cancer. Under his leadership, Allarity has achieved FDA Fast Track designation, formed key research collaborations, and presented clinical data showing landmark median overall survival of ovarian cancer patients.Company Bio:Allarity Therapeutics (NASDAQ: ALLR) is a clinical-stage biopharma company developing personalized cancer treatments guided by its proprietary DRP® companion diagnostic platform. The company's lead asset, stenoparib, is a novel, orally available dual PARP and WNT pathway inhibitor being evaluated in Phase 2 trials for advanced ovarian cancer. With headquarters in the U.S. and a research facility in Denmark, Allarity is committed to improving patient outcomes through precision oncology. Learn more at www.allarity.com

Send us a textIn this episode of the WTR Small-Cap Spotlight, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company's rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy's work on real‑time EEG and brain entropy as a potential biomarker, the company's financing,  regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

Tim Lu, CEO of Senti Bio, joins In Vivo to discuss how programmable cell therapies are solving oncology's targeting problem. Lu explains the logic-gated approach behind SENTI-202, an allogeneic CAR-NK therapy for relapsed/refractory AML that achieved 50% response rates in Phase 1 while avoiding the dose-limiting toxicities that have plagued other AML cell therapies. We cover the Phase 1 ASH 2025 data showing 39% complete remission rates (all MRD-negative) with 7.6-month median duration, the rationale for using NK cells over T cells, and why synthetic biology's three-target logic gates can distinguish cancer from healthy bone marrow cells. Lu also discusses plans for pivotal trials following RMAT designation, expansion into solid tumors, and where biotech innovation is accelerating versus where clinical translation bottlenecks remain. For biopharma professionals tracking cell therapy innovation, synthetic biology applications, and AML treatment advances.

Peachtree Corners continues to push forward on what “smart city” can really mean—and in this in-person episode of Peachtree Corners Life, host Rico Figliolini sits down with City Councilman Phil Sadd (Post 1, District 1) to unpack the biggest initiatives shaping the city right now. From public safety innovation to trails, traffic, redevelopment, and housing, Phil walks through what's happening, why it matters, and what residents can expect next.Leading the conversation is a new Drone as First Responder pilot that can launch automatically from certain 911 priority calls—arriving on scene in seconds to provide real-time awareness, improve safety, and support de-escalation before officers arrive. The episode also covers major quality-of-life and economic development efforts including Crooked Creek Trail, workforce/affordable homeownership in Mechanicsville, updates on The Forum redevelopment, the new public innovation park Curiosity Corner, and upcoming mobility projects like the Peachtree Parkway lane conversion and the Winter's Chapel corridor multi-use path open house.Key takeawaysDrone as First Responder (DFR) is launching as a pilot with Brinc (integrated with Motorola's dispatch ecosystem), and Peachtree Corners is one of five partner cities—and the only one in Georgia.Crooked Creek Trail is a major long-term project (about 1.3 miles plus spurs) with heavy environmental and safety constraints due to waterway/EPA requirements; construction is still roughly two years out.Mechanicsville workforce homeownership plan uses ARPA funds for land acquisition (about five acres) and a public-private build model with price caps and anti-flip protections to keep homes affordable long-term.The Forum redevelopment is moving toward execution: Barnes & Noble relocation enables a 125-room boutique hotel on the corner; multifamily plans are updated to below 300 units, with parking decks designed to be visually screened by buildings; target start is early 2027 (funding-dependent).Curiosity Corner is a public innovation park in Technology Park with shaded seating + connectivity, plus testing for things like Pipedream underground delivery, drone delivery, and EV programs; projected completion this spring.Traffic improvement on Peachtree Parkway: converting an existing southbound turn lane into a third straight-through lane to reduce bottlenecks; funded via SPLOST with state permission.Winter's Chapel multi-use path (Phase 2) open house: joint city involvement due to corridor “zigzag” boundaries; open house is Feb 12, 5–7.Public safety discussion focuses on improving the county partnership: Phil emphasizes better communication, better data/metrics, a potential satellite office in Peachtree Corners, and addressing staffing shortages rather than rushing toward a new department vote.

Retrouvez Rothen s'enflamme de 18h à 20h sur RMC.

PJ and I close out PHASE 1 of the MCU.  And good news, we're getting back together shortly to resume operations!  BUT this older one first, it sees us revisiting Joss Whedon's milestone achievement bringing together all the Marvel Heroes and adding more.  #marvel #avengers #mcu #ironman #captainamerica #hulk #robertdowneyjr #chrishemsworth #markruffalo #blackwidow #scarlettjohansson #chrisevans #tomhiddleston #loki 

This week: 116 days into a ceasefire, Israel has killed at least 481 Palestinians in Gaza.  Redevelopment plans for the Gaza Strip were met with skepticism by people there. Palestinians also questioned whether Israel intends to follow through with the next Phase of the US-brokered ceasefire plan in Gaza. Israel has killed more than 71,654 Palestinians in Gaza since October 7th, 2023. In this episode: Hind Khoudary, (@hindkhoudary), Al Jazeera Correspondent Nida Ibrahim, (@nida_aljazeera) Al Jazeera Correspondent Episode credits: This episode was produced by David Enders. Our sound designer is Alex Roldan. Our lead of audience development and engagement is Andrew Greiner and Munera AlDosari is our engagement producer. Alexandra Locke is The Take’s executive producer. Ney Alvarez is Al Jazeera's head of audio. Connect with us: @AJEPodcasts on X, Instagram, Facebook, and YouTube

Your daily news in under three minutes. At Al Jazeera Podcasts, we want to hear from you, our listeners. So, please head to https://www.aljazeera.com/survey and tell us your thoughts about this show and other Al Jazeera podcasts. It only takes a few minutes! Connect with us: @AJEPodcasts on Twitter, Instagram, Facebook, and YouTube

2026 is humanity's "activation phase." Dallisa Hocking explains that the warm-up is over; now, radical accountability for our vibration is essential. As AI shifts our reality, we face a collective identity crisis that demands we shed corporate masks and stop being bystanders. By mastering the core energies of approval, control, and safety, we can replace fear with curiosity and navigate deep shifts in our relationships. This is the moment to move beyond old systems and step into heart-centered resonance and true soul embodiment.And while this moment is collective, how it shows up in your life is deeply personal.

In this special episode, I'm taking you back to a conversation I recorded a few years ago with one of the astrologers I admire most, Demetra George.My fascination with the Dark Moon didn't come from astrology school. It grew slowly over time, through being around magical women, healers, and seekers who understood that the quietest phase of the lunar cycle carries extraordinary power.Everything truly crystallised when I read Demetra's book Mysteries of the Dark Moon. I became determined to speak with her, and after a little persistence and quite a few emails, she finally agreed.What followed was one of the most memorable conversations I've ever had about lunar wisdom, goddess traditions, and the ancient roots of astrology.In this episode, we explore why the Dark Moon isn't something to fear, what ancient astrologers really taught about feminine spirituality, and how this hidden phase of the Moon can be used for healing, insight, and renewal.This conversation also feels especially timely as I prepare for the release of my Dark Moon Oracle Cards, now available for pre order. In this episode, we cover:How Demetra George first became fascinated with goddess mythology and astrology.Why the Dark Moon represents withdrawal, regeneration, and the sacred pause before a new cycle.The inspiration behind Mysteries of the Dark Moon.The forgotten ancient name of the Third House as the House of the Goddess.How early astrological texts linked the Moon with women's rites, dreams, and divination.Demetra's interpretations of Medusa and Lilith and reclaiming feminine power.The symbolism of serpents, Kundalini energy, and feminine wisdom.How ancient priestesses used ritual, sexuality, and lunar timing for healing and regeneration.Why goddess traditions may not have vanished, but simply entered a hidden phase.Simple Dark Moon rituals you can try at home.Clearing your space, unplugging from stimulation, and inviting dreams and insight.How astrology can act as a form of remembrance rather than prediction.Why this episode mattersThis is a conversation about slowing down in a fast world.If you've ever felt drawn to lunar cycles, goddess wisdom, or the quieter spiritual spaces between endings and beginnings, this episode is for you.Finding Demetra George Find Demetra George at https://demetra-george.com/And her amazing book MYSTERIES OF THE DARK MOON here https://geni.us/darkmoonmysteriesExplore the Dark Moon with meIf listening to this episode sparks your curiosity, I've created a free guide to help you work with the Dark Moon in a grounded and supportive way.You can download it here: https://magic.moonology.com/get-dark-moon-guideIt'll show you how to use this powerful lunar phase for release, healing, and renewal so you can move into each New Moon cycle feeling clearer and more aligned. Join the Mainly Moonology inner circle: https://moonmessages.com/magical––Follow Yasmin on socials:✨ Facebook: https://www.facebook.com/yasminbolandmoonology ✨ Instagram: https://www.instagram.com/moonologydotcom/––Mainly Moonology is a podcast for people looking to manifest their dream life leveraging the power of the moon. Tune in each week for accessible moon teachings, weekly readings, discussions about the Law of Attraction, and everything in between! Follow us for more.

A typical vaccine stimulates a person's immune system, yet only a portion of the immune response actually targets the disease it's designed to protect against. However, a new technology may be changing that dynamic.In this episode, I sit down with Lou Reese, an entrepreneur who has led or co-founded several biotech companies and has been working on synthetic peptide-based active immunotherapy medicines. He's co-CEO of United Biomedical and co-founder of Vaxxinity, Cana Life, and Axxium.He's working on a product that could—if proven successful—transform our approach to treating and preventing Alzheimer's. He and his team also have a product that has shown preliminary promise in phase 1 trials in treating Parkinson's.In this episode, he also reveals an incredible story: He and his team previously developed a peptide-based active immunotherapy vaccine candidate for COVID-19, and they successfully completed Phase 1 and Phase 2 trials. Institutional backing, however, favored Pfizer and Moderna. In 2022, Lou Reese's team was invited to the White House “Summit on the Future of COVID‑19 Vaccines,” where they presented their candidate as an alternative to Pfizer's mRNA vaccine, which by then had been associated with serious side effects.In the end, their product was never approved, and related content on YouTube was marked as misinformation.Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.